Features of RUNX1-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBioPortal).

Abstract read

In one paragraph

Article in Wiener medizinische Wochenschrift (1946), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

[Clinical characteristics of RUNX1-mutated acute myeloid leukemia patients].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sarah BayatMedical School, Sigmund Freud University, Sigmund Freud Platz 3, 1020, Vienna, Austria.

Klaus GeisslerMedical School, Sigmund Freud University, Sigmund Freud Platz 3, 1020, Vienna, Austria. geissler.klaus@gmx.at.ORCID http://orcid.org/0000-0003-1921-7034

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Big data collected in large international cooperations now allow validation of findings from traditional national patient cohorts for proving consistency. In this study, we compared findings in RUNX1-mutated patients of the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) with the CMML cohort documented in cBioPortal. In the cBioPortal cohort, RUNX1-mutated patients had significantly inferior survival and AML-free survival as compared to nonmutated patients. In the ABCMML cohort, survival and AML-free survival were numerically shorter in RUNX1-mutated patients than in wildtype patients, but this did not reach significance. Regarding phenotype, in both cohorts, RUNX1-mutated patients had a significantly higher proportion of patients with thrombocytopenia and lower metric values for platelets as compared to wildtype patients. Validation of data, as we have done in this study in CMML patients using two independent cohorts, ensures the quality standards that are required for their use in clinical decision making.

Indexed as

Core Binding Factor Alpha 2 SubunitLeukemia, Myelomonocytic, ChronicMutationAgedAged, 80 and overAustriaCohort StudiesFemaleHumansMaleMiddle AgedPrognosisCore Binding Factor Alpha 2 SubunitRUNX1 protein, humanABCMMLcBioPortalChronic myelomonocytic leukemiaMutationRUNX1

Identifiers

PMID40138085

DOI10.1007/s10354-025-01074-y

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.